Skip Nav Destination
Issues
15 October 2016
-
Cover Image
Cover Image
The cover shows a section of a reactive breast cancer stained for α-SMA with high stromal content. For details, see the article by Dennison and colleagues on page 5068 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Amanda J. Walker; Suparna Wedam; Laleh Amiri-Kordestani; Erik Bloomquist; Shengui Tang; Rajeshwari Sridhara; Wei Chen; Todd R. Palmby; Jeanne Fourie Zirkelbach; Wentao Fu; Qi Liu; Amy Tilley; Geoffrey Kim; Paul G. Kluetz; Amy E. McKee; Richard Pazdur
Molecular Pathways
CCR Focus
Cancer Therapy: Clinical
Author Choice
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies
Khaldoun Almhanna; Thea Kalebic; Cristina Cruz; Jason E. Faris; David P. Ryan; JungAh Jung; Tim Wyant; Adedigbo A. Fasanmade; Wells Messersmith; Jordi Rodon
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
Al B. Benson, III; Igor Kiss; John Bridgewater; Ferry A.L.M. Eskens; Carolyn Sasse; Sandra Vossen; Jihong Chen; Chip Van Sant; Howard A. Ball; Anne Keating; Andrew Krivoshik
Personalized Medicine and Imaging
High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype
Jennifer B. Dennison; Maria Shahmoradgoli; Wenbin Liu; Zhenlin Ju; Funda Meric-Bernstam; Charles M. Perou; Aysegul A. Sahin; Alana Welm; Steffi Oesterreich; Matthew J. Sikora; Robert E. Brown; Gordon B. Mills
ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI
Elizabeth R. Gerstner; Zheng Zhang; James R. Fink; Mark Muzi; Lucy Hanna; Erin Greco; Melissa Prah; Kathleen M. Schmainda; Akiva Mintz; Lale Kostakoglu; Edward A. Eikman; Benjamin M. Ellingson; Eva-Maria Ratai; A. Gregory Sorensen; Daniel P. Barboriak; David A. Mankoff; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group; for the ACRIN 6684 Trial Group
Cancer Therapy: Preclinical
UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer
Rabia A. Gilani; Sameer Phadke; Li Wei Bao; Eric J. Lachacz; Michele L. Dziubinski; Kristoffer R. Brandvold; Michael E. Steffey; Frank E. Kwarcinski; Carrie R. Graveel; Kelley M. Kidwell; Sofia D. Merajver; Matthew B. Soellner
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani; Tetsuo Aida; Katsunobu Hagihara; Junko Yamaguchi; Chiaki Ishii; Naoya Harada; Masako Soma; Hiromi Okamoto; Masataka Oitate; Shingo Arakawa; Takehiro Hirai; Ryo Atsumi; Takashi Nakada; Ichiro Hayakawa; Yuki Abe; Toshinori Agatsuma
A Novel HSP90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer
Anna V. Gaponova; Anna S. Nikonova; Alexander Y. Deneka; Meghan C. Kopp; Alexander E. Kudinov; Natalia Skobeleva; Vladimir Khazak; Luisa S. Ogawa; Kathy Q. Cai; Kelly E. Duncan; James S. Duncan; Brian L. Egleston; David A. Proia; Yanis Boumber; Erica A. Golemis
Author Choice
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard; James W.T. Yates; Zhenfan Yang; Dong-Wan Kim; James Chih-Hsin Yang; Mireille Cantarini; Kathryn Pickup; Angela Jordan; Mike Hickey; Matthew Grist; Matthew Box; Peter Johnström; Katarina Varnäs; Jonas Malmquist; Kenneth S. Thress; Pasi A. Jänne; Darren Cross
Biology of Human Tumors
Author Choice
IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia
Eileen Boyle; Salomon Manier; Julie Lejeune; Guillemette Fouquet; Stephanie Guidez; Sarah Bonnet; Houria Debarri; Helene Demarquette; Remy Dulery; Julie Gay; Bernadette Hennache; Brigitte Onraed; Jean-Luc Faucompré; Suzanna Schraen; Thierry Facon; Hervé Avet-Loiseau; Sylvie Chevret; Veronique Leblond; Stephen Harding; Xavier Leleu
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds